Prediction of the pharmacokinetics, pharmacodynamics, and efficacy of a monoclonal antibody, using a physiologically based pharmacokinetic FcRn model

Frontiers in Immunology

Volumn 6, Issue JAN, 2015, Pages

  Chetty, Manoranjenni ^a   Li, Linzhong ^a   Rose, Rachel ^a   Machavaram, Krishna ^a   Jamei, Masoud ^a   Rostami Hodjegan, Amin ^a,b   Gardner, Iain ^a  

^a CERTARA UK LIMITED   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Efalizumab; FcRn model; Monoclonal antibodies; PBPK models; PBPK PD

Indexed keywords

EFALIZUMAB; FC RECEPTOR; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1;

ADULT; ARTICLE; COMPARTMENT MODEL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BINDING; DRUG CLEARANCE; DRUG DEGRADATION; DRUG DISPOSITION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NORMAL HUMAN; PARAMETERS; PHARMACODYNAMICS; PHARMACOKINETICS; PLASMA CONCENTRATION-TIME CURVE; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; SCORING SYSTEM;

EID: 84926681388     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00670     Document Type: Article

References (24)

1. Ferl GZ, Wu AM, Distefano JJ III. A predictive model of therapeutic monoclonal antibody dynamics and regulation by the neonatal Fc receptor (FcRn). Ann Biomed Eng (2005) 33:1640-52. doi: 10.1007/s10439-005-7410-3
2. Garg A, Balthasar JP. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. J Pharmacokinet Pharmacodyn (2007) 34:687-709. doi:10.1007/s10928-007-9065-1
3. Urva SR, Yang VC, Balthasar JP. Physiologically based pharmacokinetic model for T84.66: a monoclonal anti-CEA antibody. J Pharm Sci (2010) 99:1582-600. doi:10.1002/jps.21918
4. Chen Y, Balthasar JP. Evaluation of a catenary PBPK model for predicting the in vivo disposition of mAbs engineered for high-affinity binding to FcRn. AAPS J (2012) 14:850-9. doi:10.1208/s12248-012-9395-9
5. Shah DK, Betts AM. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. J Pharmacokinet Pharmacodyn (2012) 39:67-86. doi:10.1007/s10928-011-9232-2
6. Fronton L, Pilari S, Huisinga W. Monoclonal antibody disposition: a simplified PBPK model and its implications for the derivation and interpretation of classical compartment models. J Pharmacokinet Pharmacodyn (2014) 41:87-107. doi:10.1007/s10928-014-9349-1
7. Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet (2010) 49:633-59. doi:10.2165/11535960-000000000-00000
8. Keizer RJ, Huitema AD, Schellens JH, Beijnen JH. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet (2010) 49:493-507. doi:10.2165/11531280-000000000-00000
9. Mould DR, Green B. Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development. BioDrugs (2010) 24:23-39. doi:10.2165/11530560-000000000-00000
10. Deng R, Jin F, Prabhu S, Iyer S. Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development? Expert Opin Drug Metab Toxicol (2012) 8:141-60. doi:10.1517/17425255.2012.643868
11. Dostalek M, Gardner I, Gurbaxani BM, Rose RH, Chetty M. Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies. Clin Pharmacokinet (2013) 52:83-124. doi:10.1007/s40262-012-0027-4
12. Bauer RJ, Dedrick RL, White ML, Murray MJ, Garovoy MR. Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis. J Pharmacokinet Biopharm (1999) 27:397-420. doi:10.1023/A:1020917122093
13. Scheinfeld N. Efalizumab: a review of events reported during clinical trials and side effects. Expert Opin Drug Saf (2006) 5:197-209. doi:10.1517/14740338.5.2.197
14. Gottlieb A, Krueger JG, Bright R, Ling M, Lebwohl M, Kang S, et al. Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J Am Acad Dermatol (2000) 42:428-35. doi:10.1016/S0190-9622(00)90214-7
15. Gottlieb AB, Krueger JG, Wittkowski K, Dedrick R, Walicke PA, Garovoy M. Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. Arch Dermatol (2002) 138:591-600. doi:10.1001/archderm.138.5.591
16. Gordon KB, Papp KA, Hamilton TK, Walicke PA, Dummer W, Li N, et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA (2003) 290:3073-80. doi:10.1001/jama.290.23.3073
17. Mortensen DL, Walicke PA, Wang X, Kwon P, Kuebler P, Gottlieb AB, et al. Pharmacokinetics and pharmacodynamics of multiple weekly subcutaneous efalizumab doses in patients with plaque psoriasis. J Clin Pharmacol (2005) 45:286-98. doi:10.1177/0091270004270260
18. Ng CM, Joshi A, Dedrick RL, Garovoy MR, Bauer RJ. Pharmacokinetic-pharmacodynamic-efficacy analysis of efalizumab in patients with moderate to severe psoriasis. Pharm Res (2005) 22:1088-100. doi:10.1007/s11095-005-5642-4
19. Boehncke WH. Efalizumab in the treatment of psoriasis. Biologics Targets and Therapy (2007) 1(3):301-9.
20. Peletier LA, Gabrielsson J. Dynamics of target-mediated drug disposition. Eur J Pharm Sci (2009) 38:445-64. doi:10.1016/j.ejps.2009.09.007
21. Suzuki T, Ishii-Watabe A, Tada M, Kobayashi T, Kanayasu-Toyoda T, Kawanishi T, et al. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J Immunol (2010) 184:1968-76. doi:10.4049/jimmunol.0903296
22. Li L, Gardner I, Dostalek M, Jamei M. Simulation of monoclonal antibody pharmacokinetics in humans using a minimal physiologically based model. AAPS J (2014) 16(5):1097-109. doi:10.1208/s12248-014-9640-5
23. Gibiansky L, Gibiansky E, Kakkar T, Ma P. Approximations of the target-mediated drug disposition model and identifiability of model parameters. J Pharmacokinet Pharmacodyn (2008) 35:573-91. doi:10.1007/s10928-008-9102-8
24. Holford NH, Chan PL, Nutt JG, Kieburtz K, Shoulson I. Disease progression and pharmacodynamics in Parkinson disease-evidence for functional protection with levodopa and other treatments. J Pharmacokinet Pharmacodyn (2006) 33:281-311. doi:10.1007/s10928-006-9012-6